SAN DIEGO, Nov. 29, 2017 /PRNewswire/ -- NanoCellect Biomedical Inc., a developer of microfluidic cell sorting technologiesfor cell-based assays, today announced the completion of a $10 million Series B financing round, including convertible notes. The financing included the participation of new investors Illumina Ventures, Anzu Partners, Vertical
"We are thrilled to be backed by a stellar group of new and current investors, and view the strength of the participants as further validation of the potential of our WOLF Cell Sorter to play a significant role in modernizing cell-based assays," said Jose Morachis, Ph.D., President and Chief Executive Officer and co-founder of NanoCellect. "The proceeds from this financing will enable us to continue to expand our commercial activities and accelerate our efforts in highly promising application areas in cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery. We look forward to working together with our new partners in making cell sorting easy and accessible."
NanoCellect also announced today that Alexis Ji, Partner at Illumina Ventures, has joined the company's Board of Directors. Illumina Ventures invests in early-stage companies that are pioneering new applications of genomics and enabling precision medicine – including life sciences tools, clinical diagnostics, and therapeutics platforms.
"The ability to sort distinct populations of cells has wide-ranging applications for the research and biopharmaceutical industries," said Ji. "NanoCellect's plug-and-play, easy-to-use, and maintenance-free microfluidic solutions are a significant leap in making cell analysis and sorting more accessible and affordable. We are excited to work with NanoCellect and our co-investors as the company continues to modernize the cell discovery workflows."
About NanoCellect:NanoCellect is a life science tools company manufacturing cell sorters that use proprietary microfluidic technology. NanoCellect's WOLF cell sorter and N1 single cell plate dispenser allows researchers to perform antibody discovery, cell line development, genomic sample preparation and CRISPR genomic editing faster, safer, and without contamination. The compact, sturdy, and affordable system allows researchers to safely perform cell sorting and single-cell plating experiments at their convenience.
View original content:http://www.prnewswire.com/news-releases/nanocellect-biomedical-raises-10m-in-series-b-funding-led-by-illumina-ventures-300563330.html
SOURCE NanoCellect Biomedical Inc.
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All